Product Description
Vertex is developing VX-993 as a treatment for pain. (Sourced from: https://clinicaltrials.gov/study/NCT05653323)
Mechanisms of Action: NaV1.8 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Vertex
Company Location: BOSTON MA 02210
Company CEO: Reshma Kewalramani
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United Kingdom, United States
Active Clinical Trial Count: 8
Highest Development Phases
Phase 2: Acute Pain|Neuralgia|Neuropathic Pain|Peripheral Nervous System Diseases
Phase 1: Healthy Volunteers|Pain Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| VX24-993-103 | P2 |
Recruiting |
Neuralgia|Neuropathic Pain|Peripheral Nervous System Diseases |
2026-04-01 |
|
| VX24-993-101 | P2 |
Recruiting |
Acute Pain |
2025-10-01 |
|
| VX23-993-002 | P1 |
Recruiting |
Healthy Volunteers|Pain Unspecified |
2025-04-01 |
28% |
| VX24-993-006 | P1 |
Active, not recruiting |
Pain Unspecified|Healthy Volunteers |
2024-12-01 |